US70975L1070
© BusinessWire
15.01.2026
PEN
LISTED
NYSE
PEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Penumbra, Inc. is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock is fair to Penumbra shareholders.
Halper Sadeh encourages Penumbra shareholders to click here to learn more about their legal rights...
Themefolio
Profiler
Peergroup
© PR Newswire
29.12.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
Event: 44th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
ALAMEDA, Calif., Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
05.11.2025
PEN
LISTED
NYSE
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
News Preview
ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
03.11.2025
PEN
LISTED
NYSE
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
News Preview
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who rece...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
PEN
LISTED
NYSE
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
News Preview
ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduct...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
PEN
LISTED
NYSE
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
News Preview
ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
PEN
LISTED
NYSE
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile
News Preview
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots
ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE: PEN), The PERT Con...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
PEN
LISTED
NYSE
Penumbra, Inc. Names Shruthi Narayan as Company President
News Preview
ALAMEDA, Calif., Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025. She will continue to report to Adam Elsesser, who served in the role of President prior to this promotion and will continue...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at Upcoming Investor Conferences
News Preview
ALAMEDA, Calif., Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.
Event:
2025 Wel...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
News Preview
ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.
Event:
C...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
PEN
LISTED
NYSE
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
News Preview
ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.
Revenue of $339.5 million in the seco...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.07.2025
PEN
LISTED
NYSE
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
News Preview
ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close tha...
Themefolio
Profiler
Peergroup
© PR Newswire
16.06.2025
PEN
LISTED
NYSE
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
News Preview
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism
ALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leadin...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
PEN
LISTED
NYSE
Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
News Preview
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation expo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.05.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at Upcoming Investor Conferences
News Preview
ALAMEDA, Calif., May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.
Event:
William Bl...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
News Preview
ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.
Event: Bof...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
PEN
LISTED
NYSE
Penumbra, Inc. Reports First Quarter 2025 Financial Results
News Preview
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.
Revenue of $324.1 million in the fir...
Themefolio
Profiler
Peergroup
© PR Newswire
03.04.2025
PEN
LISTED
NYSE
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025
News Preview
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close t...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
PEN
LISTED
NYSE
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
News Preview
ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
PEN
LISTED
NYSE
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
News Preview
ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and ha...
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
PEN
LISTED
NYSE
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Financial Highlight...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
PEN
LISTED
NYSE
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
News Preview
ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025.
Event: ...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
News Preview
ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.
Event...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
PEN
LISTED
NYSE
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
News Preview
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 ConferenceFindings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health systemALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thr...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
PEN
LISTED
NYSE
Penumbra, Inc. Reports Third Quarter 2024 Financial Results
News Preview
ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024.
Revenue of $301.0 million in the...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2024
PEN
LISTED
NYSE
Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
News Preview
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company's latest computer assisted vacuum thrombectomy (CAVT™) techn...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
PEN
LISTED
NYSE
Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024
News Preview
ALAMEDA, Calif., Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time. A press release with third quarter 2024 financial results will be issued after market close...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
PEN
LISTED
NYSE
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe
News Preview
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quicklyLightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombusLightning Bolt™ 7 is desig...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Baird Global Healthcare Conference
News Preview
ALAMEDA, Calif., Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024.
Event: Baird G...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference
News Preview
ALAMEDA, Calif., Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.
Event:
Wells Fargo...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
PEN
LISTED
NYSE
Penumbra, Inc. Announces $200 Million Share Repurchase Authorization
News Preview
To Include $100 Million Accelerated Share Repurchase
ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million, allowing Penumbra to repurchase its...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2024
PEN
LISTED
NYSE
Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024
News Preview
ALAMEDA, Calif., July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time. A press release with second quarter 2024 financial results will be issued after market close tha...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the Truist Securities MedTech Conference
News Preview
ALAMEDA, Calif., June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024.
Event:
Truist Securiti...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the William Blair Growth Stock Conference
News Preview
ALAMEDA, Calif., May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, June 6, 2024.
Event:
William Blair...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2024
PEN
LISTED
NYSE
Penumbra, Inc. Reports First Quarter 2024 Financial Results
News Preview
ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024.
Revenue of $278.7 mi...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2024
PEN
LISTED
NYSE
Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference
News Preview
ALAMEDA, Calif., May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.
Event:
RBC...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
